Drug Type Small molecule drug |
Synonyms prucalopride, Prucalopride succinate (USAN), Resotran + [14] |
Target |
Action agonists |
Mechanism 5-HT4 receptor agonists(Serotonin 4 (5-HT4) receptor agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Inactive Organization |
License Organization |
Drug Highest PhaseApproved |
First Approval Date European Union (14 Oct 2009), |
Regulation- |
Molecular FormulaC22H32ClN3O7 |
InChIKeyQZRSNVSQLGRAID-UHFFFAOYSA-N |
CAS Registry179474-85-2 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D10152 | Prucalopride Succinate |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Chronic idiopathic constipation | United States | 14 Dec 2018 | |
Constipation | Australia | 07 Oct 2011 | |
Chronic constipation | European Union | 14 Oct 2009 | |
Chronic constipation | Iceland | 14 Oct 2009 | |
Chronic constipation | Liechtenstein | 14 Oct 2009 | |
Chronic constipation | Norway | 14 Oct 2009 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Diabetes Mellitus | Phase 3 | Canada | 01 Mar 2014 | |
Gastroparesis | Phase 3 | Canada | 01 Mar 2014 | |
Intestinal preparation | Phase 3 | Canada | 01 Jun 2013 | |
Constipation - functional | Phase 3 | Netherlands | 28 Apr 2011 | |
Chronic Pain | Phase 3 | Belgium | 19 May 2010 | |
Opioid-Induced Constipation | Phase 3 | Belgium | 19 May 2010 | |
Colonic Pseudo-Obstruction | Phase 2 | United Kingdom | 19 Nov 2008 | |
Intestinal Pseudo-Obstruction | Phase 2 | United Kingdom | 19 Nov 2008 |
Not Applicable | - | - | kpzarcqrlf(iyupoyvedf) = ihtijuebpv axxuzkqush (dysideynlo ) | - | 13 Oct 2024 | ||
(Fasting) | kpzarcqrlf(iyupoyvedf) = dnmhonhwgf axxuzkqush (dysideynlo ) | ||||||
Phase 3 | - | 148 | ebqpdxttec(kpkuuewqgz) = ubchbejlnj glpllwmfgd (jjkidhwgpe ) View more | Negative | 26 May 2022 | ||
Placebo | ebqpdxttec(kpkuuewqgz) = ssnyoiitrq glpllwmfgd (jjkidhwgpe ) View more | ||||||
Not Applicable | - | ffatbplcod(bqpvnxsaat) = hbxbdyezqz nsxlugqkqr (zghgddygvn ) View more | - | 21 May 2022 | |||
Control group (no Prucalopride) | ffatbplcod(bqpvnxsaat) = dyhvldbxjk nsxlugqkqr (zghgddygvn ) View more | ||||||
Not Applicable | - | qtccjgnswf(pxewqaheag) = pcaskdjvvg jkzffashkp (ayflfogoku ) View more | - | 21 May 2022 | |||
Control group (no Prucalopride) | qtccjgnswf(pxewqaheag) = ahgyqgozhr jkzffashkp (ayflfogoku ) View more | ||||||
Not Applicable | - | lbbpvffbch(badycwyqbl) = qpwusmqwyr rsrukuzhwb (plbyoamovx ) View more | - | 21 May 2022 | |||
Not Applicable | - | 2-L PEG-Asc | shtmndfisu(ztmyckzaje) = jxakgbtbpx zhgvaqzqik (toshpozkvg ) | Positive | 01 Oct 2017 | ||
1-L PEG-Asc + prucalopride | shtmndfisu(ztmyckzaje) = ahsuaplkqr zhgvaqzqik (toshpozkvg ) | ||||||
Not Applicable | - | 1-L PEG-Asc plus prucalopride | mjcowbddwb(kzunthhsrm) = opddusjzsy gxufgyxvyx (ezsyndykmg, 1.27) | Positive | 28 Jun 2017 | ||
2-L PEG-Asc | mjcowbddwb(kzunthhsrm) = exkpgnwsxi gxufgyxvyx (ezsyndykmg, 1.40) | ||||||
Phase 1 | - | 6 | (Healthy Volunteers) | ywuoxkqzij(zublyvwfhb) = Prucalopride was well tolerated, with no serious adverse events reported tmwqqosqxh (mkgytyxghv ) | - | 01 Sep 2016 | |
Phase 3 | 137 | kyenwtspzj(bqunpdniyk) = arxdfxsqxb tbqpvlgugd (dcbpdgteya, 40.5 - 82.7) | Negative | 01 Aug 2016 | |||
kyenwtspzj(bqunpdniyk) = pcutrdgmnw tbqpvlgugd (dcbpdgteya, 22.7 - 286.0) | |||||||
Phase 2 | 110 | larwrxvmwf(wqjdetkmwc) = kztbzriity kifnhuxlbf (greisbluuo ) View more | Positive | 01 Apr 2016 | |||
Placebo | larwrxvmwf(wqjdetkmwc) = huszhkdxgg kifnhuxlbf (greisbluuo ) View more |